Q2-FY26 · Nikhil Chopra
We continue to outpace the market and will continue to outpace like we will continue to outpace the market and IPM will continue to grow by 3 to 400 bits better.
JBCHEMICALSANDPHARMACEUT / language trends
Read confidence between the lines.
J B Chemicals · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q2-FY26 · Nikhil Chopra
Our chronic portfolio has grown at over 20%. Some of our key brands like Silaka, Silakart T. Silakar plane has grown at almost 14%, Silakart continues to grow at 26%.
Q2-FY26 · Nikhil Chopra
We have a good order book for rest of the world and we should see high single-digit growth in H2 in rest of the world market and South Africa also will bounce back.
Q4-FY26 · Koshel Soleni
Q4 was a period of operational reset which temporarily impacted performance. However, we expect normalization beginning in Q1 and continuing going forward.
Q4-FY26 · Aman Mata
The trade generics business is not really a focus for us from here. We're looking at only growing the branded business more.
Q4-FY26 · Sanjay Gupta
The good part is the customers are there. So JBI has all the top five customers and it has new contracts on hand. So the challenge is just the execution part.